ArticleWorld journal of urology2026
Multi-institutional evaluation of prostate specific antigen dynamics after simple prostatectomy.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Men remain at risk for prostate cancer after simple prostatectomy (SP). However, prostate cancer (PCa) screening after SP is challenging given the lack of data directing PSA surveillance and what PSA values should trigger further investigation in this setting. This study aimed to compare initial postoperative PSA measurements and PSA kinetics after SP in patients with benign pathology (benign prostate hyperplasia; BPH) to those with prostate cancer. We performed a retrospective review of all simple prostatectomies performed at two tertiary care centers in the United States between 2014 and 2022. Baseline patient demographics, oncologic diagnosis and treatment history, and preoperative and postoperative PSA values were collected. Records were divided into groups based on malignancy status (BPH alone vs. diagnosis of PCa). A total of 296 patients were identified with a history of simple prostatectomy and both pre- and postoperative PSA testing: 235 patients had no prostate cancer diagnosis and 61 had a history of prostate cancer (27 had known PCa prior to RASP, 34 had an incidental diagnosis of PCa from surgical pathologic specimen). There was no difference in preoperative PSA between the groups (9.6 ng/mL vs. 10.6 ng/mL, p = 0.12). Patients with BPH had an initial postoperative PSA value of 0.72 ng/mL compared to 1.37 ng/mL in those with cancer (p < 0.01). PSA was reduced by 89% in BPH compared to 78% in the malignant cohort (p < 0.01). PSA velocity after surgery was significantly elevated in those with underlying PCa (0.40 ng/mL/year vs. 0.004 ng/mL/year for men with BPH; p < 0.01). 21% of patients (13/61) in the malignant cohort had a PSA > 2 ng/mL after surgery compared to 4% (10/235) of patients in the benign cohort. For patients undergoing a simple prostatectomy, initial postoperative PSA checked at 3 months as well as postoperative PSA velocity may help to identify those at risk for PCa. Given these findings, the authors use an initial postoperative PSA above 1 to trigger further PCa screening, but a larger study with power to make a formal cutoff value is required.
Indexed as
Identifiers
41838166What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.